Transition from secukinumab to adalimumab in COVID-19-Induced
psoriasis flare-up treatment: a case report
Abstract: Coronavirus disease 2019 (COVID-19) is known to
trigger systemic inflammation and elicit immune responses, which may
disrupt the delicate balance of cytokines involved in psoriatic
regulation. Compared to other therapies in dermatology, biologics used
for immune-mediated dermatological diseases have been more extensively
studied during the COVID-19 pandemic. Herein, we report a case of
flare-up of previously well-controlled psoriasis shortly after infection
with COVID-19, with treatment transition from secukinumab to adalimumab.
Keywords: COVID-19; psoriasis; flare-up; adalimumab;
secukinumab